Cargando…
Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
OBJECTIVE: Derive and confirm factor structure of the Montgomery‐Åsberg Depression Rating Scale (MADRS) in patients with treatment‐resistant depression (TRD) and evaluate how the factors evident at baseline change over 4 weeks of esketamine treatment. METHODS: Two similarly‐designed, short‐term TRAN...
Autores principales: | Borentain, Stephane, Gogate, Jagadish, Williamson, David, Carmody, Thomas, Trivedi, Madhukar, Jamieson, Carol, Cabrera, Patricia, Popova, Vanina, Wajs, Ewa, DiBernardo, Allitia, Daly, Ella J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720209/ https://www.ncbi.nlm.nih.gov/pubmed/35749277 http://dx.doi.org/10.1002/mpr.1927 |
Ejemplares similares
-
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
por: Floden, Lysbeth, et al.
Publicado: (2022) -
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
por: Nijs, Michel, et al.
Publicado: (2020) -
The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
por: Daly, Ella J., et al.
Publicado: (2021) -
Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
por: Borentain, Stephane, et al.
Publicado: (2021) -
Psychometric evaluation of the Malay version of the Montgomery- Asberg Depression Rating Scale (MADRS-BM)
por: Yee, Anne, et al.
Publicado: (2015)